Hematology (all articles) | Links Medicus Content Curation & Alerts in Medicine

Consensus Paper: Diagnosis and treat-to-target management of macrophage activation syndrome in children.

24 Jun, 2022 | 11:13h | UTC

Egyptian evidence-based consensus on clinical practice guidelines for the diagnosis and treat-to-target management of macrophage activation syndrome in children – Egyptian Rheumatology and Rehabilitation

M-A: Intravenous iron vs. oral iron vs. no iron with or without erythropoiesis‐ stimulating agents for cancer patients with anemia.

23 Jun, 2022 | 10:10h | UTC

Intravenous iron versus oral iron versus no iron with or without erythropoiesis‐ stimulating agents (ESA) for cancer patients with anaemia: a systematic review and network meta‐analysis – Cochrane Library

Summary: Which combinations of medicines are best for the prevention and treatment of anaemia in people with cancer? – Cochrane Library

5-year follow up of a RCT: Ruxolitinib versus best available therapy in inadequately controlled polycythemia vera without splenomegaly.

23 Jun, 2022 | 09:55h | UTC

Ruxolitinib versus best available therapy in inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): 5-year follow up of a randomised, phase 3b study – The Lancet Haematology (link to abstract – $ for full-text)

Original Study: Ruxolitinib for the treatment of inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): a randomised, open-label, phase 3b study – The Lancet Oncology (link to abstract – $ for full-text)

Commentary on Twitter

NEW online—5-year follow up of RESPONSE-2, a randomised, phase 3b study, supports the use of ruxolitinib as a second-line therapy of choice for patients with inadequately controlled polycythaemia vera without splenomegaly #mpnsm https://t.co/yuENmcJv0P pic.twitter.com/aogZJ6gonW

— The Lancet Haematology (@TheLancetHaem) May 19, 2022

RCT: Lisocabtagene maraleucel vs. standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma.

21 Jun, 2022 | 10:48h | UTC

Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial – The Lancet (link to abstract – $ for full-text)

Single-arm Phase II trial: Direct-acting antivirals as primary treatment for hepatitis C virus–associated indolent Non-Hodgkin Lymphomas.

20 Jun, 2022 | 00:51h | UTC

Direct-Acting Antivirals as Primary Treatment for Hepatitis C Virus–Associated Indolent Non-Hodgkin Lymphomas: The BArT Study of the Fondazione Italiana Linfomi – Journal of Clinical Oncology

10-year outcomes of a RCT: Time to cure for childhood and young adult Acute Lymphoblastic Leukemia is independent of early risk factors.

20 Jun, 2022 | 00:49h | UTC

Time to Cure for Childhood and Young Adult Acute Lymphoblastic Leukemia Is Independent of Early Risk Factors: Long-Term Follow-Up of the UKALL2003 Trial – Journal of Clinical Oncology (link to abstract – $ for full-text)

Analysis of thromboembolic and thrombocytopenic events after the AstraZeneca, Pfizer, and Moderna COVID-19 vaccines in 3 Nordic countries.

15 Jun, 2022 | 11:17h | UTC

Analysis of Thromboembolic and Thrombocytopenic Events After the AZD1222, BNT162b2, and MRNA-1273 COVID-19 Vaccines in 3 Nordic Countries – JAMA Network Open

Recommendations Statement: Diagnosis and treatment of systemic mastocytosis.

14 Jun, 2022 | 11:03h | UTC

Diagnosis and treatment of systemic mastocytosis in Brazil: Recommendations of a multidisciplinary expert panel – Hematology, Transfusion and Cell Therapy

Cohort Study: Mortality among patients undergoing blood transfusion in relation to donor sex and parity.

14 Jun, 2022 | 10:56h | UTC

Mortality Among Patients Undergoing Blood Transfusion in Relation to Donor Sex and Parity: A Natural Experiment – JAMA Internal Medicine

News Release: Red blood cell units from female blood donors do not increase risk of death of transfused patients – Karolinska Institutet

Molecular international prognostic scoring system for myelodysplastic syndromes.

14 Jun, 2022 | 10:38h | UTC

Molecular International Prognostic Scoring System for Myelodysplastic Syndromes – NEJM Evidence

BSH guideline for the hematological management of major hemorrhage.

13 Jun, 2022 | 10:53h | UTC

A guideline for the haematological management of major haemorrhage: a British Society for Haematology Guideline – British Journal of Haematology

2-year follow-up of a single-arm study: Ciltacabtagene Autoleucel, an Anti–B-cell maturation antigen chimeric antigen receptor T-cell therapy, for relapsed/refractory multiple myeloma.

13 Jun, 2022 | 07:34h | UTC

Ciltacabtagene Autoleucel, an Anti–B-cell Maturation Antigen Chimeric Antigen Receptor T-Cell Therapy, for Relapsed/Refractory Multiple Myeloma: CARTITUDE-1 2-Year Follow-Up – Journal of Clinical Oncology

Original Study: Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study – The Lancet (link to abstract – $ for full-text)

Commentary on Twitter

In follow-up from CARTITUDE-1 trial of ciltacabtagene autoleucel in R/R MM, ORR was 97.9% and 82.5% had a stringent CR. 27-mo PFS was 54% and OS was 70.4% https://t.co/cnpzkg5yKM

— NatureRevClinOncol (@NatRevClinOncol) June 9, 2022

Systematic Review: Evidence-based perioperative diagnosis and management of pulmonary embolism.

9 Jun, 2022 | 10:34h | UTC

Evidence-based perioperative diagnosis and management of pulmonary embolism: A systematic review – Annals of Medicine and Surgery

Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL: primary analysis of the CAPTIVATE FD cohort.

9 Jun, 2022 | 10:17h | UTC

Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL: primary analysis of the CAPTIVATE FD cohort – Blood

International consensus classification of mature lymphoid neoplasms.

9 Jun, 2022 | 10:15h | UTC

The International Consensus Classification of Mature Lymphoid Neoplasms: A Report from the Clinical Advisory Committee – Blood

Cardiac Magnetic Resonance Imaging–based screening for cardiac sarcoidosis in patients with atrioventricular block requiring temporary pacing.

8 Jun, 2022 | 10:41h | UTC

Cardiac Magnetic Resonance Imaging–Based Screening for Cardiac Sarcoidosis in Patients With Atrioventricular Block Requiring Temporary Pacing – Journal of the American Heart Association

Invited Commentary: Managing Patients With Advanced Atrioventricular Block: The Essential Role of Cardiovascular Magnetic Resonance Imaging for Timely and Accurate Diagnosis – Journal of the American Heart Association

ESTRO ACROP and SIOPE recommendations for myeloablative total body irradiation in children.

7 Jun, 2022 | 10:52h | UTC

ESTRO ACROP and SIOPE recommendations for myeloablative total body irradiation in children – Radiotherapy & Oncology

Oncologic emergencies and urgencies: A comprehensive review.

6 Jun, 2022 | 12:06h | UTC

Oncologic emergencies and urgencies: A comprehensive review – CA: A Cancer Journal for Clinicians

Commentary on Twitter

🎯Just in time for #ASCO22 | Oncologic emergencies and urgencies: A comprehensive review https://t.co/HyZmI37tr5 @BEGouldRothberg @YaleCancer @KeithDelman
CC: @OncoAlert pic.twitter.com/57tqiLXijN

— CA: A Cancer Journal for Clinicians (@CAonline) June 2, 2022

#ASCO22 – RCT: Ibrutinib plus Bendamustine and Rituximab in untreated Mantle-Cell Lymphoma.

6 Jun, 2022 | 11:16h | UTC

Ibrutinib plus Bendamustine and Rituximab in Untreated Mantle-Cell Lymphoma – New England Journal of Medicine (link to abstract – $ for full-text)

News Release: Ibrutinib with chemoimmunotherapy improved progression-free survival for newly diagnosed mantle cell lymphoma patients – BTK inhibitor as front-line option for MCL – University of Texas M. D. Anderson Cancer Center

Commentary: Ibrutinib Added to Standard Therapy Prolongs Progression-Free Survival in Older Patients With Mantle Cell Lymphoma – The ASCO Post

#ASCO22 – Phase 1-2 single-arm study: Teclistamab in relapsed or refractory multiple myeloma.

6 Jun, 2022 | 11:11h | UTC

Teclistamab in Relapsed or Refractory Multiple Myeloma – New England Journal of Medicine

Commentary on Twitter

MajesTEC-1: Teclistamab resulted in a high incidence of deep and durable response in patients with triple-class–exposed relapsed or refractory multiple myeloma. #ASCO22 https://t.co/Nanjob1q7p pic.twitter.com/oqfaiu8MOx

— NEJM (@NEJM) June 5, 2022

#ASCO22 – RCT: Triplet therapy, transplantation, and maintenance until progression in myeloma.

6 Jun, 2022 | 11:06h | UTC

Triplet Therapy, Transplantation, and Maintenance until Progression in Myeloma – New England Journal of Medicine (link to abstract – $ for full-text)

News Release: Improved progression-free survival in multiple myeloma patients following three-drug therapy with autologous stem cell transplant – Dana-Farber Cancer Institute

Commentary on Twitter

DETERMINATION: Among adults with multiple myeloma, continuous lenalidomide maintenance therapy after triplet therapy (RVD, plus ASCT) associated with longer PFS than triplet therapy alone. #ASCO22 https://t.co/YhKgjc1Enz pic.twitter.com/cU8nefokZo

— NEJM (@NEJM) June 5, 2022